A practical reference on BDNF: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-30 and is reviewed periodically as new material appears.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid from research suppliers |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are used fresh |
| Typical storage temperature | -20 °C for lyophilized powder | Short-term transport at 2-8 °C is common |
| Common analytical method | Reverse-phase HPLC | Paired with mass spectrometry for identity confirmation |
| Common synonyms | ACTH(4-10) analogue; MEHFPGP | N-terminal methionine retained in the chain |
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
Außerdem muss den Herdfrischkonvertern extern Wärme zugeführt werden. Das bekannteste Herdfrischverfahren ist das Siemens-Martin-Verfahren. Frischwirkung und Heizwirkung gehen von einem oxidierenden Brenngas-Luft-Gemisch aus, das über den flachen Schmelzherd geleitet wird.
=== Direktreduktion === Die Nachteile des Hochofens sind die Anforderungen an die Einsatzmaterialien und der hohe Ausstoß an CO2. Der eingesetzte Eisenträger und der Koks müssen stückig und hart sein, sodass genügend Hohlräume in der Möllersäule bestehen bleiben, die das Durchströmen durch den eingeblasenen Wind gewährleisten. Zu den etablierten Direktreduktions-Verfahren zählen die Eisenschwamm- und Pelletherstellung in Drehrohröfen sowie die Corex-, Midrex- und Finex-Verfahren. Der Eisenschwamm wird in der Elektrostahlroute oder direkt für Gusseisen eingesetzt. Am weitesten verbreitet sind bisher das Midrex- bzw. HYL-Direktreduktionsverfahren, die Eisenschwamm bzw. HBI (engl. Hot Briquetted Iron) als festes Einsatzmaterial erzeugen. Dieses ist immer noch mit einer gewissen Menge von Gangart des Ausgangserzes belastet, aber der Kohlenstoffgehalt ist normalerweise nicht höher als 1 %. Das Corex-Verfahren ist neueren Datums und erzeugt ein flüssiges, roheisenähnliches Vormaterial, dessen Kohlenstoffgehalt bei ca. 3,5 bis 4 % liegt. Der Corex-Prozess ist ein zweistufiges Schmelzreduktionsverfahren (engl.: smelting-reduction), in dem Roheisen auf Basis nicht verkokter Kohle und Eisenerzen hergestellt werden kann. Ziel des Schmelzreduktionsverfahrens ist es, durch die Kombination von Schmelzprozess, Kohlevergasung und Direktreduktion flüssiges Eisen zu erzeugen, dessen Qualität dem Hochofenroheisen entspricht. Die Schmelzreduktion kombiniert den Prozess der Direktreduktion (Vorreduktion von Eisenoxid zu Eisenschwamm) mit einem Schmelzprozess (Hauptreduktion).
Der Prozess läuft also zweistufig in getrennten Aggregaten ab. Zuerst werden die Erze zu Eisenschwamm reduziert, im zweiten Schritt erfolgt die Endreduktion und das Aufschmelzen zu Roheisen. Die für den Schmelzvorgang nötige Energie liefert die Verbrennung von Kohle (nicht verkokt). Dabei entstehen große Mengen Kohlenmonoxid als Abgas, das als Reduktionsgas genutzt wird. Eine Variante der Direktreduktion wird seit 2010 mit einer Pilotanlage in IJmuiden unter dem Namen HIsarna-Prozess erprobt.
Sources: de.wikipedia.org
Der CO2-Ausstoß ist eine starke Belastung an Treibhausgasen. Deshalb gibt es Bestrebungen, die Hochofenroute abzulösen und Koks durch Wasserstoff als Reduktionsmittel zu ersetzen (H-DR). Wasserstoff reagiert im Prozess mit Eisenoxiden zu Wasserdampf. Die Reduktionsgleichung ist:
Sources: de.wikipedia.org
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.
A fraction of an intranasal dose is thought to reach the central nervous system, and this route is favoured partly for that reason. The proportion is not well characterized. Direct measurement in humans remains difficult with current methods.
Raised BDNF and NGF expression has been reported across several animal studies, which makes the signal fairly consistent. Whether the same change occurs in humans at usable doses is not established. It is best treated as a working hypothesis rather than a confirmed clinical mechanism.
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.